Clinical Trial Update: Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory

View source ↗

Summary

A completed real-world study evaluating the use of azacitidine in combination with venetoclax for frontline and relapse/refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Acute Myeloid Leukemia | Status: COMPLETED